Unknown

Dataset Information

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.


ABSTRACT:

Background

The efficacy of bevacizumab in non-small cell lung cancer (NSCLC) patients is unsatisfactory, and the selection of suitable patients is still challenging. Given the epigenetic modifications can contribute to an aberrant regulation of angiogenesis and microenvironment, we investigated DNA methylation profiles to determine clinical benefit of bevacizumab in NSCLC patients.

Methods

Genome-wide DNA methylation profiling was performed in NSCLC patients treated with chemotherapy in combination with bevacizumab. Patients were divided into better prognosis group (A group) and inferior prognosis group (B group) based on their survival. The difference of methylation patterns and respective functional enrichment analysis were performed between two groups. Prognostic DNA meth

SUBMITTER: Li B 

PROVIDER: S-EPMC9338664 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature